EUCTR2021-000028-36-DE招募中1 期
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate theEfficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults withRelapsing Multiple Sclerosis (ENSURE-1) - ENSURE-1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Immunic AG
- 入组人数
- 1,050
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Main study (DB) inclusion criteria:
- •1. Male or female patient (age =18 to =55 years)
- •2. Patients with an established diagnosis of MS according to 2017
- •McDonald Criteria
- •3. Patients with RMS comprising of relapsing remitting MS (RRMS) and active secondary progressive MS, both defined according to Lublin criteria 1996 and 2014. Patients are eligible for this trial if their disease modifying treatment has failed due to
- •efficacy, safety, or tolerability issues, if they have contraindications or no access to treatment, or if they refuse the offered MS treatment.
- •4. Active disease as defined by Lublin 2014 evidenced prior to Screening
- •a.At least 2 relapses(a) in the last 24 months before randomization, or
- •b.At least 1 relapse(a) in the last 12 months before randomization, or
- •c.A positive Gd+ MRI scan (brain and/or spine) in the last 12 months
- •prior to randomization.
- •(a) Relapses must have been assessed and documented by a physician inthe patient files.
- •5. EDSS score between 0 and 5.5 (inclusive) at SV1.
- •Female patients:
- •a. must be of non-childbearing potential, ie, surgically sterilized
- •(hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least
- •6 weeks before SV1) or postmenopausal (where postmenopausal is
- •defined as no menses for 12 months without an alternative medical
- •b. if of childbearing potential, must have a negative pregnancy test at
- •SV1 (blood test) and before the first IMP intake (Day 1 blood or urine
- •test). They must agree not to attempt to become pregnant, must not
- •donate ova, and must use a highly effective contraceptive method (see
- •below) together with a barrier method between study consent and 30
- •days after the last intake of the IMP.
- •c.highly effective forms of birth control are those with a failure rate less
- •than 1% per year and include:
- •i.oral, intravaginal, or transdermal combined (estrogen and progestogen
- •containing) hormonal contraceptives associated with inhibition of
- •ii.oral, injectable, or implantable progestogen-only hormonal
- •contraceptives associated with inhibition of ovulation.
- •iii.intrauterine device or intrauterine hormone-releasing system.
- •iv.bilateral tubal occlusion.
- •v.vasectomized partner (ie, the patient's male partner underwent
- •effective surgical sterilization before the female patient entered the
- •clinical study. and is the sole sexual partner of the female patient during
- •the clinical study).
- •vi.sexual abstinence (acceptable only if it is the patient's usual form of
- •birth control/lifestyle choice; periodic abstinence [eg, calendar,
- •ovulation, symptothermal, postovulation methods] and withdrawal are
- •not acceptable methods of contraception).
- •d.Barrier methods of contraception include:
- •ii.occlusive cap (diaphragm or cervical/vault caps) with spermicidal
- •gel/film/cream/suppository.
- •7. Male patients must agree not to father a child or to donate sperm
- •starting at SV1, throughout the clinical study, and for 30 days after the
- •last intake of the IMP. Male patients must also:
- •a. abstain from sexual intercourse with a female partner (acceptable
- •only if it is the patient's usual form of birth control/lifestyle choice), or
- •b. use adequate barrier contraception during treatment with the IMP and
- •until at least 30 days after the last intake of the IMP, and
- 另有 4 项未显示
排除标准
- •Main period (DB) exclusion criteria:
- •1. Patients with non-active secondary progressive MS and primary
- •progressive MS.
- •2. Any disease other than MS that may better explain the signs and
- •symptoms, including history of complete transverse myelitis.
- •3. Clinical signs or presence of laboratory findings suggestive for
- •neuromyelitis optica (NMO) spectrum disorders or myelin
- •oligodendrocyte glycoprotein (MOG)-IgG-associated encephalomyelitis.
- •4. Any MRI finding, which puts in question the MS diagnosis, including
- •but not limited to a longitudinally extensive spinal cord lesion.
- •5. History of malignancy of any organ system (other than localized basal
- •cell carcinoma of the skin or adequately treated cervical cancer), treated
- •or untreated, within the past 5 years, regardless of whether there is
- •evidence of full remission at the current time.
- •6. Any active and uncontrolled coexisting autoimmune disease, other
- •than MS (except for type 1 diabetes mellitus and inflammatory bowel
- •7. An MS relapse ending within 30 days before SV1 and/or during the
- •Screening Period (until Day 1).
- •8. Any corticosteroid treatment for relapse given within 30 days before SV2.
- •Please refer to protocol for further DB exclusion criteria (Therapy,
- •immune response, other medical history and concomitant disease as well as general exclusion criteria).
- •Extension period (OL) exclusion criteria:
- •1.Any ongoing, clinically significant (as assessed by the investigator)
- •TEAE (started after intake of IMP) or laboratory abnormality (including
- •blood chemistry and urinalysis) that, upon discretion of the investigator,
- •should prohibit further treatment with study medication in this trial(a).
- •2.Significant treatment non-compliance (defined as having taken <70%
- •of study medication) or study non-compliance during the MP (as
- •assessed by the investigator, in consultation with the medical monitor),
- •and/or inability or unwillingness to follow instructions by study
- •3.Multiple significant protocol deviations during the MP that are
- •assessed by the investigator, in consultation with the medical monitor,
- •to negatively affect further patient cooperation in this study.
- •4.Use of experimental/investigational drug (with the exception of
- •COVID-19 vaccines approved by emergency use authorization) and/or
- •participation in another clinical trial of an investigational drug
- •throughout the duration of the EP open-label treatment period.
- •(a) If a TEAE(s) is the reason for exclusion from the EP open-label
- •treatment period, the eligibility can be re-assessed up to 12 weeks
- •following the last treatment in the MP.
研究者
相似试验
招募中
3 期
A Study of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis(ENSURE-2)CTRI/2022/04/041596Immunic AG
招募中
3 期
A Study of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE 1)CTRI/2022/02/040605Immunic AG
招募中
1 期
ot applicableRelapsing Multiple SclerosisMedDRA version: 27.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-000028-36-BGImmunic AG1,050
进行中（未招募）
1 期
ot ApplicableRelapsing Multiple SclerosisMedDRA version: 27.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-000028-36-LTImmunic AG1,050
尚未招募
3 期
A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)G37 NULLPER-033-22Immunic AG